• Debate Flares over Using AI to Detect COVID-19 in Lung Scans

    A series of studies, starting as a steady drip and quickening to a deluge, has reported the same core finding amid the global spread of COVID-19: Artificial intelligence could analyze chest images to accurately detect the disease in legions of untested patients.
    Casey Ross writes in STAT that the results promised a ready solution to the shortage of diagnostic testing in the U.S. and some other countries and triggered splashy press releases and a cascade of hopeful headlines. But in recent days, the initial burst of optimism has given way to an intensifying debate over the plausibility of building AI systems during an unprecedented public health emergency.

  • Not All Genetic Tests Convey Risk in the Same Way, Scientists Warn

    Research presented virtually at the World Congress of Cardiology meeting over the weekend suggests that some direct-to-consumer or lab-based genetic tests may not convey the full risk of inherited disease. Scientists analyzed de-identified data from more than 14,000 patients who were referred to genetic testing for cardiomyopathy, an inherited condition that can lead to heart failure. Patients were subject to two different kinds of genetic sequencing, and the results were compared to a simpler genetic test that only screens for nine variants in two genes known to cause cardiomyopathy. If patients had been screened using the simpler test, 96% of the patients who actually had a risk for cardiomyopathy would have been falsely reassured that they didn’t have a such a risk. The scientists behind the study warn against relying on limited tests that paint an inaccurate picture.  

  • How Sick Will the Coronavirus Make You? The Answer May Be in Your Genes

    COVID-19, caused by the new pandemic coronavirus, is strangely—and tragically—selective. Only some infected people get sick, and although most of the critically ill are elderly or have complicating problems such as heart disease, some killed by the disease are previously healthy and even relatively young. Jocelyn Kaiser writes in Science that researchers are now gearing up to scour the patients’ genomes for DNA variations that explain this mystery. The findings could be used to identify those most at risk of serious illness and those who might be protected, and they might also guide the search for new treatments.

  • Lessons from Italy’s Response to Coronavirus

    As policymakers around the world struggle to combat the rapidly escalating Covid-19 pandemic, they find themselves in uncharted territory. Much has been written about the practices and policies used in countries such as China, South Korea, Singapore, and Taiwan to stifle the pandemic. Gary P. Pisano , Raffaella Sadun, and Michele Zanini write in the Harvard Business Review that unfortunately, throughout much of Europe and the United States, it is already too late to contain Covid-19 in its infancy, and policymakers are struggling to keep up with the spreading pandemic. In doing so, however, they are repeating many of the errors made early on in Italy, where the pandemic has turned into a disaster. “The purpose of this article is to help U.S. and European policymakers at all levels learn from Italy’s mistakes so they can  recognize and address the unprecedented challenges presented by the rapidly expanding crisis,” they write.

     

  • Understanding the Economic Shock of Coronavirus

    As the coronavirus continues its march around the world, governments have turned to proven public health measures, such as social distancing, to physically disrupt the contagion. Yet, doing so has severed the flow of goods and people, stalled economies, and is in the process of delivering a global recession. Economic contagion is now spreading as fast as the disease itself.
    Philipp Carlsson-Szlezak , Martin Reeves, and Paul Swartz write in the Harvard Business Review that this didn’t look plausible even a few weeks ago. As the virus began to spread, politicians, policy makers, and markets, informed by the pattern of historical outbreaks, looked on while the early (and thus more effective and less costly) window for social distancing closed. Now, much further along the disease trajectory, the economic costs are much higher, and predicting the path ahead has become nearly impossible, as multiple dimensions of the crisis are unprecedented and unknowable.
    “In this uncharted territory, naming a global recession adds little clarity beyond setting the expectation of negative growth. Pressing questions include the path of the shock and recovery, whether economies will be able to return to their pre-shock output levels and growth rates, and whether there will be any structural legacy from the coronavirus crisis,” they write.

  • MIT-Based Team Works on Rapid Deployment of Open-Source, Low-Cost Ventilator

    One of the most pressing shortages facing hospitals during the COVID-19 emergency is a lack of ventilators. These machines can keep patients breathing when they no longer can on their own, and they can cost around $30,000 each. Now, a rapidly assembled volunteer team of engineers, physicians, computer scientists, and others, centered at MIT, is working to implement a safe, inexpensive alternative for emergency use, which could be built quickly around the world. The goal is to support rapid scale-up of device production to alleviate hospital shortages.

  • Preventing Quantum Cyberattacks

    From defense and health information to social networking and banking transactions, communications increasingly rely on cryptographic security amid growing fears of cyberattacks. However, can such sensitive data be unhackable?

  • Coronavirus: A New Type of Vaccine Using RNA Could Help Defeat COVID-19

    Scientists had already identified the polio virus in 1916, but it took 50 more years to develop a vaccine. That vaccine eradicated polio in the U.S. in less than a decade. Vaccines are one of the most effective modern disease-fighting tools.
    Sanjay Mishra and Robert Carnahan write in The Conversation that as of this writing, the fast-spreading COVID-19 has already infected almost half a million worldwide, and has killed over 22,000 patients. There is an urgent need for a vaccine to prevent it from infecting and killing millions more. But traditional vaccine development takes, on average, 16 years.
    So how can scientists quickly develop a vaccine for SARS-CoV-2?
    “As immunologists, we are trying to expedite development of vaccines and antibody therapeutics,” Mishra and Carnahan write, noting that the Pandemic Protection Platform Program run by the Defense Advanced Research Agency (DARPA) of the U.S. Department of Defense uses fast-track “sprints” to help us identify and deploy protective antibody treatments against viral outbreaks, such as SARS-CoV-2. Now other colleagues of ours are working on expediting a new type of vaccine for COVID-19.

  • Labs Are Experimenting with New – but Unproven – Methods to Create a Coronavirus Vaccine Fast

    This is the idea behind vaccines: give the body an opportunity to build defenses against a virus it may encounter in the future.Jean Peccoud writes in The Conversation that with the coronavirus literally making time a matter of life and death, nearly 50 public and private labs are turning to newer, safer and faster methods to develop a coronavirus vaccine. There are three categories of vaccines:
    Protein-based vaccines: Rather than injecting the whole virus, it is possible to vaccinate a person with a single virus component. The pieces most commonly used are proteins from the surface of a virus.Two companies, Sanofi and Novawax, are both developing protein vaccines based on the SARS-CoV-2 spike protein, the tower-shaped structures on the surface of the new coronavirus that causes COVID-19.
    Gene-based vaccines: Theoretically, the simplest and fastest way to make a vaccine would be to have a person’s own cells produce minute quantities of the viral protein that trigger an immune response. To do that researchers are turning to genetics.As of yet, there are no DNA vaccines currently approved by the FDA for human use and the success of this method has been limited. But there is promise. In 2016, several groups developed candidate Zika vaccines using this technology and at least one company, INOVIO Pharmaceuticals, Inc. is developing INO-4800, a DNA vaccine candidate for the coronavirus. Notable in the U.S. is Moderna, and on March 16, the National Institutes of Health started a clinical trial of Moderna’s lead coronavirus vaccine candidate, mRNA-1273.
    Friendly virus vaccines: The main issue with gene-based vaccines is getting the DNA or RNA to where it needs to be. One elegant way to solve this challenge is to use a harmless virus as a delivery system. This technique is being pursued by a few companies around the world. For example, Hong Kong-based CanSino Biologics is inserting the coronavirus gene that codes for the spike protein into an adenovirus. They used this strategy to produce the first government-approved Ebola vaccine, and clinical trials of an engineered adenovirus that would protect against the coronavirus have already started in China.

  • A Guide to the Vaccines and Drugs that Could Fight Coronavirus

    The global race to make a vaccine and treatment for the Covid-19 coronavirus is well underway as the epicenter of the pandemic is now shifting toward the United States.
    The virus has already shown it has the potential to kill — particularly vulnerable groups, like older adults and people with underlying health conditions. But people of all ages are at risk of severe illness and death.
    Julia Belluz, Umair Irfan, and Brian Resnick write in Vox that the virus is also highly contagious. And there’s a lot we don’t know about it since it was only discovered mere months ago. For these reasons, the World Health Organization (WHO) declared COVID-19 a global public health emergency back in January (and later said it had become a pandemic).
    “As this new virus makes its way around the globe, the public health tools we have to control its spread are blunt, often not implemented correctly or fast enough,” they write. “They’re already having big economic and social side effects. Health officials are relying on tactics like quarantines and social distancing while hospitals (which fear equipment shortages) are using oxygen and fever reducers, like ibuprofen, to treat people.”
    The good news is that the world is in better shape to come up with a medical solution — a coronavirus drug or vaccine — than it’s ever been. “Within a couple of weeks of discovering the outbreak, Chinese scientists sequenced the virus’s genome and shared it with the world. The structure of the virus was revealed shortly thereafter. These developments now hold the key to creating what could end this outbreak for good: vaccines and pharmaceutical treatments.”

  • The Next Frontier in Coronavirus Testing: Identifying the Full Scope of the Pandemic, Not Just Individual Infections

    Scientists are starting to roll out new blood tests for the coronavirus, a key development that, unlike the current diagnostic tests, will help pinpoint people who are immune and reveal the full scope of the pandemic.
    Andrew Joseph writes in STAT that tThe “serological” tests — which rely on drawn blood, not a nasal or throat swab — can identify people who were infected and have already recovered from Covid-19, including those who were never diagnosed, either because they didn’t feel particularly sick or they couldn’t get an initial test. Scientists expect those individuals will be safe from another infection for at least some time — so the tests could signal who could be prioritized to return to work or serve as a frontline health worker.

  • How Monoclonal Antibodies Might Prove Useful Against the Coronavirus

    When our bodies are invaded by a virus, our immune systems make particular proteins called antibodies to help fight off infection.
    NPR reports that scientists working to quell the COVID-19 pandemic think it will be possible to figure out which antibodies are most potent in quashing a coronavirus infection, and then make vast quantities of identical copies of these proteins synthetically.
    This approach — using infusions of what are known as monoclonal antibodies – has already proved to be effective in fighting a variety of diseases, such as rheumatoid arthritis and some cancers.
    Several efforts are underway to turn this approach on the coronavirus, with hopes of getting something ready for human testing within the next few months.

  • Blood Plasma from Survivors Will Be Given to Coronavirus Patients

    In people who have recovered, plasma is teeming with antibodies that may fight the virus. But the treatment beginning in New York is experimental.
    Denise Grady writes in the New York Times that doctors in New York will soon be testing the idea that blood from coronavirus survivors help other people fight the illness? The tests will be made with hospitalized patients who are seriously ill.
    Blood from people who have recovered can be a rich source of antibodies, proteins made by the immune system to attack the virus. The part of the blood that contains antibodies, so-called convalescent plasma, has been used for decades to treat infectious diseases, including Ebola and influenza.

  • Just How Many of Us Have Actually Had Coronavirus? Far More Than the Official Figures Suggest

    Uncertainty over asymptomatic or mild cases means true number of those who have, or have had, COVID-19, likely to be much higher.
    Amid the uniquely unsettling novelty the coronavirus epidemic has brought, one thing is more uncertain than any other: how many of us have, or have had, the virus? Harry de Quetteville writes in the Telegraph that on Tuesday, for example, Italy’s civil protection chief, Dr. Angelo Borrelli, briefed reporters with the latest statistics: cases up 3,612 to 54,030. The problem was that, earlier in the day, he had suggested there might be as many as 600,000. Asked to account for the difference, he said his earlier answer had taken into account asymptomatic cases. So what is it? 54,000 or 600,000?
    Italy is not alone. Earlier this week, the Self-Defense Forces Central Hospital in Tokyo published a report into the Diamond Princess cruise ship, which was quarantined in February with more than 800 of the 3,711 people on board eventually diagnosed with COVID-19. 
    According to the report, cited by the Japan Times, four-fifths of those infected showed no symptoms or just mild symptoms. Scans showed their lungs had suffered some physical consequences from the virus, but the patients had not been led by their symptoms to believe they were infected. Quite the reverse.
    “One way or another, it is clear that far more of us have, or have had, Covid-19, than the official figures tell us. But how many more? Only mass testing will give us a real picture of what is happening,” de Quetteville writes.

  • COVID Deniers: How Shadowy Social Media Groups Are Spreading Myths and Conspiracy about Coronavirus

    Conspiracies and fake news about Covid-19 are spreading across millions of users’ timelines.
    Two weeks ago an anti-vaccine Facebook group called ‘We Brought Vaxxed to the UK’ started to disseminate a new and dangerous contagion: misinformation about Covid-19.
    Paul Nuki writes in the Telegraph that its posts promote xenophobia, conspiracy theories and erroneous medical information about the disease and how it might be treated.
    One post claimed China was using the outbreak to cull the elderly, another suggested hand sanitiser causes cancer and a “probiotic yogurt suppository” was recommended as a cure.
    The group is just one of some 50 social media accounts being tracked by the Center for Countering Digital Hate (CCDH), a charity dedicated to preventing false and divisive lies and myths spreading across the web.
    “I took our file on these groups to Facebook executives to express our deep concern”, said CCDH chief executive Imran Ahmed. “But nearly two weeks later, they have still not taken action to enforce their own policies and remove them.”